Example: marketing
Reflection paper on expectations for electronic source ...
responsibilities of the investigator and the sponsor as defined in GCP should be applied, in order to ensure the reliability of the data. The use of electronic records for clinical data results in new issues as well as a need to reiterate
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
GCP inspection metrics 2018-2019 (12-02-21)
assets.publishing.service.gov.ukreported in one GCP Inspection report. Where an inspection was conducted before 1st April 2019 and the other inspections (e.g. associated investigator site or further visit) were conducted after 1st April 2019 (e.g. sponsor site then the investigator site(s)) the findings from the inspections
Guideline on the content, management and archiving of …
www.ema.europa.eu(Directive 2001/20/EC and Directive 2005/28/EC), as well as ICH E6 Good Clinical Practice (GCP) Guideline (‘ICH GCP guideline’), regarding the structure, content, management and archiving of the ... The investigator TMF is often referred to as the investigator site file (ISF). The TMF for the trial, both of the sponsor and of the ...
COMMONLY-USED ABBREVIATIONS AND ACRONYMS IN …
www.rochester.eduGCP Good Clinical Practice . ... IB Investigator’s Brochure IBC Institutional Biosafety Committee ICF Informed Consent Form ICH International Conference on Harmonisation ... SMO Site Management Organization SO Safety Officer SOP Standard Operating Procedure
A Phase II, Randomized, Double -blind, Placebo -controlled ...
clinicaltrials.gov• International Conference on Harmonisation, E6 Good Clinical Practice: Consolidated Guideline. • All applicable laws and regulations, including, without limitation, data privacy laws and regulations. • Regulatory requirements for reporting serious …